Javier Cortes, MD, PhD, on Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer

Posted: Thursday, January 2, 2020

Javier Cortes, MD, PhD, of the IOB Institute of Oncology, talks about whether checkpoint inhibitor treatment is going to be a feasible option for some breast cancer patients, and whether this class of drugs is easier for patients to tolerate, in general, than single-agent cytotoxic regimens.